Spontaneous remission of malignant tumors is rare and the biological mechanism of such remission has not been addressed. We report the case of a 71-year-old Japanese patient with non-small cell lung cancer with a right hilar tumor and pleural dissemination that spontaneously regressed. NY-ESO-1 is a cancer/testis antigen that can elicit specific immune responses in patients with cancer. Strong anti-NY-ESO-1 immunity was detected in this patient. His tumor cells expressed NY-ESO-1 and MHC class I molecules. Anti-NY-ESO-1 immunity might have contributed to spontaneous remission in this patient.
Introduction
Spontaneous remission is extremely rare in patients with non-small cell lung cancer (NSCLC). Any underlying mechanism of this remission remains unclear [1] . A systemic reaction, such as an immune response to tumors, seemed to be a possible causative mechanism. However, there have been no reports indicating immunoreaction-mediated spontaneous remission in patients with NSCLC.
NY-ESO-1 was originally identified in esophageal cancer by serological expression cloning using autologous patient serum and found to be a cancer/testis antigen that is expressed in cancer and testis, but not in normal adult somatic tissues [2, 3] . This antigen has made one of the fastest transitions from molecular, cellular, and immunological descriptions to a vaccine and immunotherapy candidate. NY-ESO-1 has already been tested in various formulations in more than 30 clinical trials worldwide, and its main characteristic resides in its capacity to elicit spontaneous antibody and T-cell responses in a proportion of patients with cancer [4] . Here, we present the case of a patient with NSCLC that spontaneously regressed, possibly mediated by anti-NY-ESO-1 immunity.
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Case report
A 71-year-old man was referred to Goto Central Hospital, Nagasaki, Japan in November 2004 for further examination of abnormal shadows on his chest x-ray.
A chest computed tomography (CT) revealed a right hilar tumor, measuring 3 x 3 cm, and right multiple focal pleural thickenings (Fig. 1A) . The patient underwent a thoracoscopy and tumor specimens were collected from the right pleural thickening. The pathological diagnosis was poorly differentiated adenocarcinoma with positive staining for cytokeratin 7 and negative staining for cytokeratin 20 (Fig. 1B) . The clinical diagnosis was c-T4N0M0 stage IIIB NSCLC.
The patient refused to receive any treatment at that time. A follow-up chest CT showed the disappearance of pleural dissemination and shrinkage of the right hilar tumor (Fig. 1A) .
Materials and Methods
Blood was drawn from the patient with informed consent. Collected serum samples were frozen until use. Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifugation. CD4 and CD8 T-cells were obtained from PBMC using CD4 and CD8 microbeads, respectively, with columns and in AIM-V (Invitrogen, Carlsbad, CA) with 5% heat-inactivated pooled human serum with 10 units/ml IL-2 (Takeda Chemical Industry, Osaka, Japan) and 10 ng/ml IL-7 (Peprotech, London, UK) in a 24-well plate at 37°C in a 5% CO 2 atmosphere for 12 days. IFNJ secretion assays with 2 x 10 5 cells were performed according to manufacturer's protocol [6] . Immunohistochemistry was performed as described elsewhere [7] . Fig. 2A) . We also observed strong CD4 and CD8 T-cell responses specific to NY-ESO-1 in an assay for interferon gamma (IFNJ secretion. Thus, integrated anti-NY-ESO-1 immunity consisting of antibody with CD4 and CD8 T-cell responses was detected in the patient (Fig. 2B ).
Immunohistochemical staining was performed for NY-ESO-1, MHC class I, and CD8 + T-cells. Cytoplasmic expression of NY-ESO-1 was observed in 50-60%
cancer cells (Fig. 3A) . MHC class I was stained on the cell surface of 30-40% cancer cells (black arrows) (Fig. 3B ). CD8 + T-cells were observed in the interface between the stromal and tumor tissues (black arrows) and also within the tumor tissue (white arrows) (Fig. 3C ). CD8 + T-cells in tumor tissue were counted using a 40x objective lens in 10 fields and more than 30 cells were observed in each 7 field. In addition, double staining of CD25 (brown) and FOXP3 (red) showed that CD25 + FOXP3 + T-cells (black arrows) were mainly distributed in stromal tissue and that CD25 + FOXP3 -T-cells (white arrows) were observed in tumor tissue in this patient (Fig. 3D ).
As shown in Figure 1A , a follow-up chest CT scan in February 2006 showed the disappearance of pleural dissemination, while the right hilar tumor had increased to 4.5 x 3 cm. Once the patient agreed to receive treatment, radiation (a total of 60 Gy in 30 fractions) against the tumor was started in March,
2006; this was effective and resulted in a partial response [5] . As of September 2007, the patient was doing well and no recurrence of pleural dissemination had been observed.
Discussion
We detected a high titer of IgG antibody specific to NY-ESO-1 from a patient with NSCLC that spontaneously regressed. We also observed anti-NY-ESO-1 CD4
and CD8 T-cell responses from his lymphocytes. Values higher than 0.1% were considered to be significant. 
